![]() |
|
|
Vol. 281, Issue 3, 1186-1190, 1997
First Department of Medicine, To elucidate whether a newly developed antiallergic drug, the
triazolopyridazin derivative TAK-225, alters airway mucociliary clearance and, if so, what the mechanism of action is, we measured mucociliary transport in the rabbit tracheal mucosa ex vivo
and ciliary motility of the tracheal epithelium in vitro.
Mucociliary transport function was determined by the transport rate of
Evans blue dye that had been placed on the mucosal surface above the carina. Oral administration of TAK-225 (0.3-30 mg/kg) increased Evans
blue transport toward the larynx in a dose-dependent manner. Addition
of TAK-225 caused a rapid and sustained increase in the ciliary beat
frequency of tracheal epithelium, as assessed by photoelectric method;
the maximal increase from the base-line value was 25.1 ± 4.6%
(P < .01), and the concentration required to produce a
half-maximal effect (EC50) was 3.1 ± 0.8 × 10
7 M. This effect was greatly attenuated by pretreatment
with the cAMP antagonist adenosine 3
,5
-cyclic monophosphorothioate,
but not by Ca++-free medium containing ethylene glycol-bis
[
-aminoethyl ether] N,N,N
,N
-tetraacetic acid
and [1,2-bis(2)aminophenoxy]ethane N,N,N
,N
-tetraacetic
acid-acetomethoxy ester. Incubation of tracheal epithelium with TAK-225
increased intracellular cAMP contents in a concentration-dependent
manner. These results suggest that TAK-225 enhances airway mucociliary
clearance probably through cAMP-mediated stimulation of ciliary
motility of airway epithelium.
Copyright © by The American Society for Pharmacology and Experimental Therapeutics